Key Highlights
- Shares are trading up 10.62% at $4.25 versus a prior close of $3.84.
- NDV-01 showed durable complete response in 76% of patients at 12 months.
- FDA alignment supports a path to Phase 3 registrational trials.
Relmada (NASDAQ:RLMD) shares are trading up 10.62% at $4.25 today as investors turn their attention back to its lead bladder cancer program. The stock sits within a 52-week range of $2.19 to $8.00 and is rebounding from a prior close of $3.84 on Volume of 1.62 million shares.
Relmada Therapeutics is a Coral Gables, Florida-based clinical-stage biotechnology company founded in 2004 that develops therapies in oncology and central nervous system disorders. Its lead program, NDV-01, is a sustained-release intravenous formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer. The company has 17 employees.
NDV-01 Phase 2 Results Remain the Core of the Story
Relmada has reported strong Phase 2 data for NDV-01, with 76% of patients showing a durable complete response at 12 months. The company has also described FDA alignment on registrational pathways that support the program's advance toward a Phase 3 program.
Non-muscle invasive bladder cancer is a setting where intravesical therapies are the standard approach, and a sustained-release formulation of gemcitabine and docetaxel is designed to extend drug exposure in the bladder. The Phase 2 response rate at the 12-month mark is the headline figure investors have focused on.
A Small-Cap With a Wide 52-Week Range
Relmada's shares have ranged from $2.19 to $8.00 over the past year, and the stock's trailing loss per share is $0.90. At $4.25 the stock remains roughly 47% below its 52-week high while sitting well above the low.
Company news flow in recent days has included an announcement about its upcoming financial report and a Leadership update involving its chief financial officer, giving traders additional items to follow alongside the clinical program.
Phase 3 Planning Is the Next Milestone for Relmada
With a double-digit gain in hand, the focus stays on how quickly Relmada can move NDV-01 into a registrational trial. The company's upcoming Quarterly Report should give further detail on cash, spending and timelines.






Please wait processing your request...